Key clinical point: Among patients with ankylosing spondylitis or undifferentiated spondyloarthritis who had not recently experienced anterior uveitis, risk was highest with secukinumab and etanercept.
Major finding: After excluding patients who had experienced anterior uveitis in the past year, secukinumab and etanercept carried higher adjusted risks for first on-treatment anterior uveitis (hazard ratios, 2.23 and 1.80, respectively) relative to adalimumab.
Study details: A prospective cohort study of 3,568 patients with ankylosing spondylitis or undifferentiated spondyloarthritis starting a biologic disease-modifying antirheumatic drug.
Disclosures: Dr. Lindström disclosed that he had no relevant conflicts of interest. The study did not receive any specific funding. Dr. Haroon disclosed consulting for Amgen, Abbvie, Eli Lilly, Janssen, Novartis, and UCB.
Lindström U et al. Ann Rheum Dis. 2020;79[suppl 1]:9, Abstract OP0014.